Replies to post #134266 on NorthWest Biotherapeutics Inc (NWBO)

[wavelengthy]

Building on your 2nd point, let's compare the suggested attendees from the 2016 vs 2017 Cancer Vaccines conference:

2016: https://web.archive.org/web/20170103064942/smi-online.co.uk/pharmaceuticals/uk/cancer-vaccines/[/url][tag]insert-text-here[/tag]

WHO SHOULD ATTEND
The following job titles in the field of cancer vaccine/immunology:
Head/Director/CEO
Director of Translational Research
Medical Scientist
Chief Medical Officer
Principal Scientist
R&D Project Leader
Chief Scientific Officer
Formulation Scientist
//
Activartis Biotech GmbH; Agalimmune Limited; ALmac Group; Amgen Limited; AstraZeneca; Avacta Life Sciences; Barts Cancer Institute; Bavarian Nordic G Mb H; Biosafe Sa; BIRD-C GmbH & CoKEG; Boehringer Ingelheim Pharma GmbH & Co. KG; Cancer Rearch UK; Cancer Research UK; Cancer Vaccines Ltd; DanDrit Biotech; Family Management Corporation; GP; Immunicum AB (publ); INSERM; IntelliCyt; IntelliCyt Corporation; Kings College London; National Cancer Institute; NHS Locum; Northwest Biotherapeutics; Northwest Biotherapeutics Inc; Nottingham Trent University; Ovacure; Plymouth University Peninsula Schools of Medicine and Dentistry, The Institute of Translational and Stratified Medicine; Rakvakcina Kft; Roche; Salamanca Group; Shionogi Limited; Solving Kids' Cancer; St Georges Hospital Medical School; St George's, University of London; Stanford University Cancer Institute; Statens Serum Institute; The John van Geest Cancer Research Centre; THERAVECTYS; Thomson Reuters; TRON Translational Oncology Mainz; UCB-Celltech; UCL Cancer Institute; UCLH BioResources; University Of Southampton; Vaccinogen;


2017: https://www.smi-online.co.uk/pharmaceuticals/uk/cancer-vaccines?utm_medium=www.cancervaccinesevent.com&utm_source=P-221&utm_campaign=EACR

WHO SHOULD ATTEND
Directors, senior scientists, project leaders, research directors of: Immuno-oncology, vaccine development, oncology, molecular medicine, immunobiology
//
4-Antibody AG; Abzena; Agenus; Amal Therapeutics; Anticancer Fund; Antwerp University; BioNTech AG; Boehringer Ingelheim Pharma GmbH & Co. KG; Cancer Research UK; ccit-denmark; Center into DiseasesFor Public Health Research; Exicure Inc.; Genentech, Inc.; Hadassah Medical School; Health Protection Scotland; ImmunoCellular Therapeutics Ltd; IO Biotech; IP & Science; Kings College London; Merck Research Laboratories; Midatech Pharma PLC; MilliporeSigma (Merck, KGaA); MSD; Northwest Biotherapeutics; Oxford BioMedica (U K) Limited; ProImmune Ltd.; Ross Univ Sch Of Med; Shionogi; SKAN AG; Talentmark Limited; The Life Sciences Division; Translational Oncology (TRON); UCL; Woodford Investment Management;